Gliomas Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Gliomas clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Solid TumorSolid Tumor, AdultNeuroblastoma+12 more
Memorial Sloan Kettering Cancer Center23 enrolled2 locationsNCT06104488
Recruiting
Phase 2

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Diffuse Intrinsic Pontine Gliomas (DIPG)Progressive DIPGRefractory DIPG+2 more
Nationwide Children's Hospital60 enrolled20 locationsNCT06838676
Recruiting
Not Applicable

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Brain CancerGliomasRecurrent CNS Tumors+3 more
National Cancer Institute (NCI)80 enrolled1 locationNCT07374692
Recruiting
Phase 1Phase 2

5G-PEARL: Paxalisib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary Gliomas
Institute of Cancer Research, United Kingdom64 enrolled1 locationNCT07391215
Recruiting
Phase 1Phase 2

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom182 enrolled3 locationsNCT06630260
Recruiting
Not Applicable

A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma

Recurrent GlioblastomaRecurrent Gliomas
Alpha Tau Medical LTD.10 enrolled1 locationNCT06910306
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Kidney CancersHead and Neck TumorsSmall Cell Lung Cancers+3 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting

AI-assisted Diagnosis of Malignant Brain Tumors

Brain Metastases, AdultLymphomaGliomas+1 more
Second Affiliated Hospital, School of Medicine, Zhejiang University3,000 enrolled2 locationsNCT07198256
Recruiting
Not Applicable

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression

GlioblastomaGrade III GliomaHigh-Grade Gliomas+1 more
Medical University of Warsaw35 enrolled2 locationsNCT06975332
Recruiting
Phase 1

5G-EMERALD: Amivantamab in Malignant Brain Tumours

Glioblastoma Multiforme (GBM)Malignant Primary GliomasGlioblastoma Multiform (Grade IV Astrocytoma)+1 more
Institute of Cancer Research, United Kingdom12 enrolled2 locationsNCT06632236
Recruiting
Early Phase 1

A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

Gliomas
JIANG LONGWEI3 enrolled1 locationNCT06828341
Recruiting

SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)

MeningiomaSchwannomaBrain Tumor, Primary+2 more
Seoul National University Hospital3,000 enrolled1 locationNCT05254197
Recruiting
Phase 1Phase 2

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Brain MetastasesBrain TumorBrain Cancer+4 more
Essen Biotech85 enrolled1 locationNCT06640582
Recruiting
Phase 2

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

ParagangliomaPheochromocytomaSolid Tumor Cancer+6 more
Fundación de investigación HM25 enrolled1 locationNCT06607692